We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

An Open-Label, Single and Multiple Oral Dose Pharmacokinetic Study of Vigabatrin in Infants With Infantile Spasms

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01413711
Recruitment Status : Withdrawn
First Posted : August 10, 2011
Last Update Posted : September 13, 2012
Information provided by (Responsible Party):
Lundbeck LLC

Brief Summary:
The primary objective of the study is to evaluate vigabatrin pharmacokinetics (PK) in neonates receiving vigabatrin for infantile spasms (IS); and to determine the safety of vigabatrin.

Condition or disease Intervention/treatment Phase
Infantile Spasms Drug: Vigabatrin Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: An Open-Label, Single and Multiple Oral Dose Pharmacokinetic Study of Vigabatrin in Infants With Infantile Spasms
Study Start Date : June 2012
Estimated Primary Completion Date : September 2013

Arm Intervention/treatment
Experimental: Vigabatrin Drug: Vigabatrin
Oral vigabatrin as a single 25 mg/kg dose on Days 1 and 5, 25 mg/kg twice a day (50 mg/kg daily dose, orally) on Days 2-4
Other Name: Sabril®

Primary Outcome Measures :
  1. Non-compartmental pharmacokinetic profile of vigabatrin after oral administrations in infants(>=1 and <6 months of age) [ Time Frame: 24 hrs post dose on Day 1 and 12 hrs post dose on Day 5 ]
    Serial blood for plasma generation will be collected on Days 1 and 5 and vigabatrin concenrations determined to the determine the pharmacokinetic profile of vigabatrin

Secondary Outcome Measures :
  1. To determine the safety of vigabatrin following oral dose administrations in infants (>=1 and <6 months of age) [ Time Frame: Safety collected throughout the 5-day study ]
    Safety and tolerability parameters such as adverse events, clinical safety laboratory tests and vital signs will be summarised using descriptive statistics

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   1 Month to 6 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The patient's parent or legally authorized representative is able to read and understand the Patient Information Sheet and Informed Consent Form.
  • The patient's legally authorized representative has signed the Informed Consent Form.
  • The patient has IS, diagnosed according to the International League Against Epilepsy (ILAE) criteria.
  • The patient is a full term (38 weeks gestation) male or female, aged >=1 month to <6 months at the time of enrollment.
  • The patient's length and body weight for gestational age is >=5th and <=95th percentile, according to Centers for Disease Control and Prevention (CDC) Growth Charts.

Exclusion Criteria:

  • The patient is currently being treated or has been previously treated with vigabatrin.
  • The patient is a member of the site personnel's immediate family.
  • The patient takes or has taken disallowed recent or concomitant medication or it is anticipated that the patient will require treatment with at least one of the disallowed concomitant medications during the study.
  • The patient has a history of severe drug allergy or hypersensitivity, or known hypersensitivity to the investigational medicinal product (IMP) or the excipients (povodone/iodine) of the IMP.
  • The patient has any other disorder for which the treatment takes priority over treatment of IS or is likely to interfere with study treatment or impair treatment compliance.
  • The patient has been treated with any IMP within 30 days or 5 half lives (whichever is longer) prior to the Screening Visit.
  • The patient has a disease or takes medication that could, in the investigator's opinion, interfere with the assessments of safety, tolerability, or efficacy, or interfere with the conduct or interpretation of the study.
  • The patient has been diagnosed or is judged by the investigator to have anemia.
  • The patient has been diagnosed or is judged by the investigator to have renal insufficiency.
  • The patient's parent or legally authorized representative is, in the investigator's opinion, unlikely or unwilling to comply with the protocol or the patient is unsuitable for any reason.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01413711

Sponsors and Collaborators
Lundbeck LLC
Layout table for investigator information
Study Director: Email contact via H. Lundbeck A/S LundbeckClinicalTrials@lundbeck.com
Layout table for additonal information
Responsible Party: Lundbeck LLC
ClinicalTrials.gov Identifier: NCT01413711    
Other Study ID Numbers: 13453A
First Posted: August 10, 2011    Key Record Dates
Last Update Posted: September 13, 2012
Last Verified: September 2012
Keywords provided by Lundbeck LLC:
Area under the curve
Maximum plasma concentration
Time to maximum concentration
Additional relevant MeSH terms:
Layout table for MeSH terms
Spasms, Infantile
Neuromuscular Manifestations
Neurologic Manifestations
Nervous System Diseases
Epilepsy, Generalized
Brain Diseases
Central Nervous System Diseases
Epileptic Syndromes
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
GABA Agents
Neurotransmitter Agents
Physiological Effects of Drugs